<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">Itonis, Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:8410b6a6-31f7-408d-b195-77b74afce874;id=34590</id>
  <rights
    type="text">Copyright 2018, Itonis, Inc.</rights>
  <updated>2018-09-26T18:11:57Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/NU1lLzsR6ee0jHZ3hi0uBw==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/NU1lLzsR6ee0jHZ3hi0uBw==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/09/26/1576777/26289/en/Itonis-Inc-announces-Emesyl-Plus-homeopathic-nasal-spray-containing-Premium-Hemp-Oil.html</id>
    <title
      type="text">Itonis, Inc. announces “Emesyl® Plus” homeopathic nasal spray containing Premium Hemp Oil</title>
    <published>2018-09-26T18:11:57Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/09/26/1576777/26289/en/Itonis-Inc-announces-Emesyl-Plus-homeopathic-nasal-spray-containing-Premium-Hemp-Oil.html" />
    <category
      term="OTC Markets:ITNS"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US4657331033"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="left">LAGUNA HILLS, Calif., Sept.  26, 2018  (GLOBE NEWSWIRE) -- Itonis, Inc. (OTC PINKSHEETS: ITNS)<br></p>]]></content>
    <dc:identifier>1576777</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Wed, 26 Sep 2018 18:11 GMT</dc:modified>
    <dc:subject>Product / Services Announcement</dc:subject>
    <dc:keyword>Emesyl</dc:keyword>
    <dc:keyword>homeopathic</dc:keyword>
    <dc:keyword>ITNS</dc:keyword>
    <dc:keyword>pharmaceutical</dc:keyword>
    <dc:keyword>nausea relief</dc:keyword>
    <dc:keyword>Cannabis Hemp Oil</dc:keyword>
    <dc:keyword>Emesyl Plus</dc:keyword>
    <dc:keyword>Itonis</dc:keyword>
    <dc:keyword>nasal spray</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/01/02/1277235/26289/en/Itonis-Inc-Provides-Update-for-its-Emesyl-Anti-nausea-Product-Sales.html</id>
    <title
      type="text">Itonis, Inc. Provides Update for its Emesyl® Anti-nausea Product Sales</title>
    <published>2018-01-02T19:48:45Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/01/02/1277235/26289/en/Itonis-Inc-Provides-Update-for-its-Emesyl-Anti-nausea-Product-Sales.html" />
    <category
      term="OTC Markets:ITNS"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US4657331033"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p>Laguna Hills, CA, Jan.  02, 2018  (GLOBE NEWSWIRE) -- <strong></strong></p>]]></content>
    <dc:identifier>1277235</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Tue, 02 Jan 2018 19:48 GMT</dc:modified>
    <dc:subject>Press releases</dc:subject>
    <dc:keyword>homeopathic</dc:keyword>
    <dc:keyword>Emesyl</dc:keyword>
    <dc:keyword>pharmaceutical</dc:keyword>
    <dc:keyword>nausea relief</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/09/27/1045204/0/en/Itonis-Inc-Announces-Its-Emesyl-Anti-Nausea-Product-is-Again-Available-for-Purchase-via-Amazon-com.html</id>
    <title
      type="text">Itonis, Inc. Announces Its Emesyl Anti-Nausea Product is Again Available for Purchase via Amazon.com</title>
    <published>2016-09-27T13:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/09/27/1045204/0/en/Itonis-Inc-Announces-Its-Emesyl-Anti-Nausea-Product-is-Again-Available-for-Purchase-via-Amazon-com.html" />
    <content
      type="html"><![CDATA[<p align="left"><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 27, 2016) - </span>Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that its Emesyl<sup>®</sup> anti-nausea homeopathic product is again available for purchase via Amazon.com.</p>]]></content>
    <dc:identifier>1045204</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/09/20/1045201/0/en/Itonis-Inc-Signs-Facebook-Ad-Campaign-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product-in-California-Market.html</id>
    <title
      type="text">Itonis, Inc. Signs Facebook Ad Campaign for Its Emesyl Anti-Nausea Homeopathic Product in California Market</title>
    <published>2016-09-20T14:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/09/20/1045201/0/en/Itonis-Inc-Signs-Facebook-Ad-Campaign-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product-in-California-Market.html" />
    <content
      type="html"><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 20, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that it has signed an agreement with Facebook to run online advertisements over a 30-day period in its California Market for its Emesyl® anti-nausea Homeopathic product.</p>]]></content>
    <dc:identifier>1045201</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/09/02/1045200/0/en/Itonis-Inc-to-Air-Emesyl-Commercial-Spots-in-the-Washington-DC-Market-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product.html</id>
    <title
      type="text">Itonis, Inc. to Air Emesyl Commercial Spots in the Washington, DC Market for Its Emesyl Anti-Nausea Homeopathic Product</title>
    <published>2016-09-02T15:18:55Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/09/02/1045200/0/en/Itonis-Inc-to-Air-Emesyl-Commercial-Spots-in-the-Washington-DC-Market-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product.html" />
    <content
      type="html"><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 02, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></content>
    <dc:identifier>1045200</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html</id>
    <title
      type="text">Itonis, Inc. Announces 10,000 Commercial Spots for Its Emesyl Anti-Nausea Relief Have Begun</title>
    <published>2016-07-21T14:09:03Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html" />
    <content
      type="html"><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - July 21, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></content>
    <dc:identifier>1045199</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
    <media:content
      medium="image"
      type="image/jpeg"
      width="600"
      url="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/Tier1-5d69dfd1735ba382be218bdedd205a5d.jpg">
      <media:text
        type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html">
    <img src="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/Tier1-5d69dfd1735ba382be218bdedd205a5d.jpg" width="600" align="left" border="0" alt="Photo" title="The platform consists of 3 tiers on the following popular cable TV networks." />
  </a>
</p><br clear="all" />]]></media:text>
      <media:credit
        role="publishing company">GlobeNewswire Inc.</media:credit>
    </media:content>
    <media:content
      medium="image"
      type="image/jpeg"
      width="600"
      url="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/map-7d3aea1a7c27ad16a7e1bef32227e5b0.jpg">
      <media:text
        type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html">
    <img src="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/map-7d3aea1a7c27ad16a7e1bef32227e5b0.jpg" width="600" align="left" border="0" alt="Photo" title="The following map shows where the ads are being aired within the states." />
  </a>
</p><br clear="all" />]]></media:text>
      <media:credit
        role="publishing company">GlobeNewswire Inc.</media:credit>
    </media:content>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/07/12/1045198/0/en/Itonis-Inc-Announces-the-Results-of-a-Case-Study-Testing-the-Effects-of-Its-Emesyl-Nasal-Relief-on-Severe-Nausea.html</id>
    <title
      type="text">Itonis, Inc. Announces the Results of a Case Study Testing the Effects of Its Emesyl Nasal Relief on Severe Nausea</title>
    <published>2016-07-12T13:30:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/07/12/1045198/0/en/Itonis-Inc-Announces-the-Results-of-a-Case-Study-Testing-the-Effects-of-Its-Emesyl-Nasal-Relief-on-Severe-Nausea.html" />
    <content
      type="html"><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - July 12, 2016) - </span>Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></content>
    <dc:identifier>1045198</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2015/02/11/1045197/0/en/Itonis-Pharmaceutical-s-EMESYL-TM-Nausea-Relief-Convenience-Store-Test-Market-Begins-in-Lodi-California.html</id>
    <title
      type="text">Itonis Pharmaceutical's EMESYL(TM) Nausea Relief Convenience Store Test Market Begins in Lodi, California </title>
    <published>2015-02-11T18:43:53Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2015/02/11/1045197/0/en/Itonis-Pharmaceutical-s-EMESYL-TM-Nausea-Relief-Convenience-Store-Test-Market-Begins-in-Lodi-California.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Feb 11, 2015) - Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></content>
    <dc:identifier>1045197</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2015/02/10/1045196/0/en/Itonis-Distribution-of-Its-EMESYL-TM-Nausea-Relief-Seeking-Marketing-Evaluation-to-Air-Infomercial-With-As-Seen-On-TV.html</id>
    <title
      type="text">Itonis Distribution of Its EMESYL(TM) Nausea Relief Seeking Marketing Evaluation to Air Infomercial With "As Seen On TV" </title>
    <published>2015-02-10T14:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2015/02/10/1045196/0/en/Itonis-Distribution-of-Its-EMESYL-TM-Nausea-Relief-Seeking-Marketing-Evaluation-to-Air-Infomercial-With-As-Seen-On-TV.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Feb 10, 2015) - Itonis (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased that its distributor (Hensley Brothers Distribution, LLC) has shipped Itonis' EMESYL&#8482; Nausea Relief product to As Seen On TV Productions for efficacy and marketing evaluation. (<a rel="nofollow" href="http://www.accesswire.com/425615/Hensley-Brothers-Distribution-LLC-Ships-Itonis-Emesyl-Nausea-Relief-to-As-Seen-On-TV-Productions" title="">http://www.accesswire.com/425615/Hensley-Brothers-Distribution-LLC-Ships-Itonis-Emesyl-Nausea-Relief-to-As-Seen-On-TV-Productions</a>) </p>]]></content>
    <dc:identifier>1045196</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/08/12/1045194/0/en/Itonis-Pharmaceuticals-Announces-First-Emesyl-R-Manufacturer-Production-Release-Date.html</id>
    <title
      type="text">Itonis Pharmaceuticals Announces First Emesyl(R) Manufacturer Production Release Date </title>
    <published>2014-08-12T12:30:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/08/12/1045194/0/en/Itonis-Pharmaceuticals-Announces-First-Emesyl-R-Manufacturer-Production-Release-Date.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Aug 12, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></content>
    <dc:identifier>1045194</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/06/25/1045192/0/en/Itonis-Pharmaceuticals-Authorizes-Start-of-Emesyl-R-Inaugural-Production-Run.html</id>
    <title
      type="text">Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run </title>
    <published>2014-06-25T12:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/06/25/1045192/0/en/Itonis-Pharmaceuticals-Authorizes-Start-of-Emesyl-R-Inaugural-Production-Run.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - <strong>Itonis, Inc. </strong>(<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl&#174; homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. </p>]]></content>
    <dc:identifier>1045192</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/06/19/1045190/0/en/Itonis-Pharmaceuticals-Completes-Final-Package-Design-Enabling-Start-of-Emesyl-R-Production.html</id>
    <title
      type="text">Itonis Pharmaceuticals Completes Final Package Design, Enabling Start of Emesyl(R) Production </title>
    <published>2014-06-19T14:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/06/19/1045190/0/en/Itonis-Pharmaceuticals-Completes-Final-Package-Design-Enabling-Start-of-Emesyl-R-Production.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 19, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that the final product packaging and bottle label designs for its Emesyl&#174; over-the-counter homeopathic product for nausea relief are now complete. The finalized packaging design includes the 800 product phone number, the product information website, the product UPC code, and a brand new visual look that is very appealing to consumers.&#160;New pictures of the final box and bottle designs can be found on the company's website news tab at # <a rel="nofollow" href="http://www.itonisholdings.com/news" title="">http://www.itonisholdings.com/news</a>. </p>]]></content>
    <dc:identifier>1045190</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/06/02/1045189/0/en/Itonis-Pharmaceuticals-Receives-NDC-Number-From-FDA-to-Enable-Production-and-Marketing-of-Emesyl-R-Product.html</id>
    <title
      type="text">Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product </title>
    <published>2014-06-02T21:34:26Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/06/02/1045189/0/en/Itonis-Pharmaceuticals-Receives-NDC-Number-From-FDA-to-Enable-Production-and-Marketing-of-Emesyl-R-Product.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that the U.S. Food &amp; Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl&#174; over-the-counter homeopathic product for nausea relief. </p>]]></content>
    <dc:identifier>1045189</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/05/08/1045185/0/en/Itonis-Inc-Signs-First-Retail-Merchant-for-MyECheck-s-Point-of-Sale-Mobile-Payment-Application.html</id>
    <title
      type="text">Itonis, Inc. Signs First Retail Merchant for MyECheck's Point of Sale Mobile Payment Application </title>
    <published>2014-05-08T13:30:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/05/08/1045185/0/en/Itonis-Inc-Signs-First-Retail-Merchant-for-MyECheck-s-Point-of-Sale-Mobile-Payment-Application.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - May 8, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has signed a letter of intent with Valley Organics Inc. for retail use of MyECheck's patented mobile payment application that will facilitate point of purchase transactions for medical marijuana. </p>]]></content>
    <dc:identifier>1045185</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/24/1045181/0/en/Itonis-Inc-Readies-Preliminary-Packaging-Design-for-Project-Cloud9-Cannabinoid-Based-Product.html</id>
    <title
      type="text">Itonis, Inc. Readies Preliminary Packaging Design for Project "Cloud9" Cannabinoid-Based Product </title>
    <published>2014-04-24T13:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/24/1045181/0/en/Itonis-Inc-Readies-Preliminary-Packaging-Design-for-Project-Cloud9-Cannabinoid-Based-Product.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 24, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today unveiled its preliminary packaging design for its cannabinoid-based product that had been code named Project "Cloud9." For an available image of the packaging design, please use this link: <a rel="nofollow" href="http://itonisholdings.com/wp-content/uploads/2014/04/Itonis_Cloud9_Package_IMG_2200-800x801.jpg" title="">http://itonisholdings.com/wp-content/uploads/2014/04/Itonis_Cloud9_Package_IMG_2200-800x801.jpg</a>.</p>]]></content>
    <dc:identifier>1045181</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/22/1045178/0/en/Itonis-Pharmaceuticals-in-Final-Steps-of-NDC-Registration-With-FDA-for-Emesyl-Product.html</id>
    <title
      type="text">Itonis Pharmaceuticals in Final Steps of NDC Registration With FDA for Emesyl Product </title>
    <published>2014-04-22T13:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/22/1045178/0/en/Itonis-Pharmaceuticals-in-Final-Steps-of-NDC-Registration-With-FDA-for-Emesyl-Product.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 22, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to share an update from its manufacturer that the Company's Emesyl&#8482; anti-nausea product is in its final steps of completing the NDC registration with the Food and Drug Administration ("FDA"), and is being readied for the first production run.&#160;While the process has taken longer than expected, the Company is pleased with recent progress to deliver Emesyl&#8482; to market. </p>]]></content>
    <dc:identifier>1045178</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/16/1045174/0/en/Itonis-Inc-Signed-Exploratory-Analysis-Trial-for-Cloud9-Project-With-Valley-Organics-Inc.html</id>
    <title
      type="text">Itonis, Inc. Signed Exploratory Analysis Trial for Cloud9 Project With Valley Organics Inc. </title>
    <published>2014-04-16T13:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/16/1045174/0/en/Itonis-Inc-Signed-Exploratory-Analysis-Trial-for-Cloud9-Project-With-Valley-Organics-Inc.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 16, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has signed an agreement with Valley Organics Inc. to start a 30-day "Exploratory Analysis Trial" for the Company's cannabinoid-based product that is presently named as its Cloud9 project.</p>]]></content>
    <dc:identifier>1045174</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/08/1045170/0/en/Itonis-Inc-to-Profit-From-Transactional-Revenues-by-Marketing-Its-Licensed-MyECheck-Mobile-App-to-Marijuana-Dispensary-Market.html</id>
    <title
      type="text">Itonis, Inc. to Profit From Transactional Revenues by Marketing Its Licensed MyECheck Mobile App to Marijuana Dispensary Market </title>
    <published>2014-04-08T17:25:46Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/08/1045170/0/en/Itonis-Inc-to-Profit-From-Transactional-Revenues-by-Marketing-Its-Licensed-MyECheck-Mobile-App-to-Marijuana-Dispensary-Market.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 8, 2014) - &#160;Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced its plans to market its MyECheck proprietary mobile app to the massively exploding marijuana dispensary market in order to facilitate cash-free point of sale transactions to gain transactional fee revenues. </p>]]></content>
    <dc:identifier>1045170</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/03/1045167/0/en/Itonis-Inc-Developing-Cannabinoid-Based-Cloud9-Product.html</id>
    <title
      type="text">Itonis, Inc. Developing Cannabinoid-Based "Cloud9" Product </title>
    <published>2014-04-03T13:30:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/03/1045167/0/en/Itonis-Inc-Developing-Cannabinoid-Based-Cloud9-Product.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 3, 2014) - &#160;Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it is in the final phase of its research and development of a cannabinoid-based product presently named "Cloud9&#8482;."</p>]]></content>
    <dc:identifier>1045167</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/01/1045165/0/en/Itonis-Inc-Joins-the-National-Cannabis-Industry-Association-to-Advance-Into-the-Medical-Marijuana-Products-and-Services-Sector.html</id>
    <title
      type="text">Itonis, Inc. Joins the National Cannabis Industry Association to Advance Into the Medical Marijuana Products and Services Sector </title>
    <published>2014-04-01T13:00:00Z</published>
    <updated>2024-12-14T19:49:41Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/01/1045165/0/en/Itonis-Inc-Joins-the-National-Cannabis-Industry-Association-to-Advance-Into-the-Medical-Marijuana-Products-and-Services-Sector.html" />
    <content
      type="html"><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 1, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has joined the National Cannabis Industry Association (NCIA) as a member in a part of the Company's preparations to expand into the medical marijuana products and services sector. The Company is positioning itself for tremendous opportunities in this vibrant sector in unison with its recent app licensing agreement with MyECheck, Inc.</p>]]></content>
    <dc:identifier>1045165</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Itonis, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified>
  </entry>
</feed>